{"denoms":[{"counts":[{"groupId":"BG000","value":"38"},{"groupId":"BG001","value":"14"},{"groupId":"BG002","value":"11"},{"groupId":"BG003","value":"2"},{"groupId":"BG004","value":"65"}],"units":"Participants"}],"groups":[{"description":"Subjects with AITL received tipifarnib as monotherapy. Tipifarnib was administered with food at a starting dose of 300 mg orally BID on Days 1 - 21 of 28-day treatment cycles.\n\nIn the absence of unmanageable toxicity, treatment may have been continued as long as the investigator considered that the treatment was providing clinical benefit for up to 12 months since the subject's enrollment. Treatment may have continued beyond 12 months upon agreement by the investigator and sponsor if there was documented evidence of sustained clinical benefit.","id":"BG000","title":"Cohort AITL"},{"description":"Subjects with PTCL-NOS (not including subjects with PTCL-NOS CXCL12+) received tipifarnib as monotherapy. Tipifarnib was administered with food at a starting dose of 300 mg orally BID on Days 1 - 21 of 28-day treatment cycles.\n\nIn the absence of unmanageable toxicity, treatment may have been continued as long as the investigator considered that the treatment was providing clinical benefit for up to 12 months since the subject's enrollment. Treatment may have continued beyond 12 months upon agreement by the investigator and sponsor if there was documented evidence of sustained clinical benefit.","id":"BG001","title":"Cohort PTCL-NOS"},{"description":"Subjects with PTCL-NOS CXCL12+ (not including subjects with PTCL-NOS) received tipifarnib as monotherapy. Tipifarnib was administered with food at a starting dose of 300 mg orally BID on Days 1 - 21 of 28-day treatment cycles.\n\nIn the absence of unmanageable toxicity, treatment may have been continued as long as the investigator considered that the treatment was providing clinical benefit for up to 12 months since the subject's enrollment. Treatment may have continued beyond 12 months upon agreement by the investigator and sponsor if there was documented evidence of sustained clinical benefit.","id":"BG002","title":"Cohort PTCL-NOS, CXCL12+"},{"description":"Subjects with other indications (including ALCL-ALK negative and PTCL-subtype not specified per protocol) received tipifarnib as monotherapy. Tipifarnib was administered with food at a starting dose of 300 mg orally BID on Days 1 - 21 of 28-day treatment cycles.\n\nIn the absence of unmanageable toxicity, treatment may have been continued as long as the investigator considered that the treatment was providing clinical benefit for up to 12 months since the subject's enrollment. Treatment may have continued beyond 12 months upon agreement by the investigator and sponsor if there was documented evidence of sustained clinical benefit.","id":"BG003","title":"Cohort Other"},{"description":"Total of all reporting groups","id":"BG004","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"10.7","value":"65.50"},{"groupId":"BG001","spread":"13.7","value":"65.73"},{"groupId":"BG002","spread":"12.6","value":"65.74"},{"groupId":"BG003","spread":"12.0","value":"56.68"},{"groupId":"BG004","spread":"11.6","value":"65.32"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"16"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"5"},{"groupId":"BG003","value":"1"},{"groupId":"BG004","value":"24"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"22"},{"groupId":"BG001","value":"12"},{"groupId":"BG002","value":"6"},{"groupId":"BG003","value":"1"},{"groupId":"BG004","value":"41"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"2"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"4"}],"title":"Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"36"},{"groupId":"BG001","value":"14"},{"groupId":"BG002","value":"9"},{"groupId":"BG003","value":"2"},{"groupId":"BG004","value":"61"}],"title":"Not Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Ethnicity (NIH/OMB)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"23"},{"groupId":"BG001","value":"13"},{"groupId":"BG002","value":"9"},{"groupId":"BG003","value":"1"},{"groupId":"BG004","value":"46"}],"title":"White"},{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"1"},{"groupId":"BG004","value":"3"}],"title":"Black or African American"},{"measurements":[{"groupId":"BG000","value":"12"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"12"}],"title":"Asian"},{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"2"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"4"}],"title":"Other"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Race/Ethnicity, Customized","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"18"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"5"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"26"}],"title":"Performance Score 0"},{"measurements":[{"groupId":"BG000","value":"13"},{"groupId":"BG001","value":"10"},{"groupId":"BG002","value":"6"},{"groupId":"BG003","value":"2"},{"groupId":"BG004","value":"31"}],"title":"Performance Score 1"},{"measurements":[{"groupId":"BG000","value":"7"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"8"}],"title":"Performance Score 2"}]}],"description":"Performance Score:\n\n* 0: Fully active, able to carry on all predisease performance without restriction.\n* 1: Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, e.g., light housework, office work.\n* 2: Ambulatory and capable of all self-care but unable to carry out any work activities. Up and about more than 50% of waking hours.","paramType":"COUNT_OF_PARTICIPANTS","title":"Eastern Cooperative Oncology Group (ECOG) Performance Score","unitOfMeasure":"Participants"}],"populationDescription":"The All Subjects as Treated (ASaT) Population consists of all enrolled subjects who received at least 1 dose of tipifarnib."}